Alice Boakyewaa
Research Subjects
Alice Boakyewaa has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Baakwa De-Graft Miah
West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Legon, Accra, Ghana
1 shared publication - Florence Agyemang-Bioh
National Public Health and Reference Laboratory, Harley Street, Korle Bu Teaching Hospital, Accra P.O. Box GP300, Ghana
1 shared publication - Gifty Boateng
National Public Health and Reference Laboratory, Ghana Health Service, Accra, Ghana
1 shared publication - Joycelene Akua Attu1 shared publication
- Lorreta Antwi1 shared publication
- Nathan Kofi Antwi1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Public Health
- Vol. 2026 (1)
IFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection
Background: The diagnosis of Mycobacterium tuberculosis infection increasingly relies on interferon‐gamma release assay (IGRA) technologies. Despite their usefulness, inconsistency in IFN‐ γ responses and the persistence of indeterminate results remain problematic across IGRA platforms. The present study aimed to comparatively assess three commercial IGRA assays (TBF‐ELISA, TBF‐FIA, and QFT‐Plus) with emphasis on IFN‐ γ production and factors influencing indeterminate results. Methods: The study employed a cross‐sectional design and was implemented at the National Public Health and Reference Laboratory in Ghana. A total of 1148 individuals were enrolled consecutively and stratified according to their TB exposure status. Parallel testing of collected blood samples was performed with the three IGRA assays. IFN‐ γ production was quantified, and the rate of indeterminate results was analyzed. Multivariate regression analyses were performed to assess determinants of IFN‐ γ levels and indeterminate results. Results: Significant quantitative differences in IFN‐ γ responses were observed across platforms ( p < 0.001). Active TB was the strongest predictor of IFN‐ γ release, with highest mean levels detected by TBF‐FIA (6.18 IU/mL), followed by TBF‐ELISA (3.11 IU/mL) and QFT‐Plus (2.80–2.96 IU/mL). TBF‐ELISA showed strong concordance with minimal bias versus QFT‐Plus (≤0.167 IU/mL), whereas TBF‐FIA demonstrated substantial proportional bias (>1.5 IU/mL). Indeterminate rates differed significantly (TBF‐FIA 13%, QFT‐Plus 8%, TBF‐ELISA 6%; Cochran’s Q test, p < 0.001). Demographic factors were not associated with assay failure; however, sample collection sites were significantly related. Notably, healthcare workers and TB contacts showed lower IFN‐ γ responses than expected. Conclusion: While all three IGRAs effectively differentiate TB infection status, the variability in IFN‐ γ responses and indeterminate rates is an indication that they may not be interchangeable. TBF‐FIA demonstrated the highest variability, requiring further investigation. The findings suggest that each test has its own strengths and limitations, thus, the need for selective use depending on the clinical setting and testing purpose.
- 1 January 2026
- Published by Wiley in Advances in Public Health
- Vol. 2026 (1)
Open AccessIFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection
Background: The diagnosis of Mycobacterium tuberculosis infection increasingly relies on interferon‐gamma release assay (IGRA) technologies. Despite their usefulness, inconsistency in IFN‐ γ responses and the persistence of indeterminate results remain problematic across IGRA platforms. The present study aimed to comparatively assess three commercial IGRA assays (TBF‐ELISA, TBF‐FIA, and QFT‐Plus) with emphasis on IFN‐ γ production and factors influencing indeterminate results. Methods: The study employed a cross‐sectional design and was implemented at the National Public Health and Reference Laboratory in Ghana. A total of 1148 individuals were enrolled consecutively and stratified according to their TB exposure status. Parallel testing of collected blood samples was performed with the three IGRA assays. IFN‐ γ production was quantified, and the rate of indeterminate results was analyzed. Multivariate regression analyses were performed to assess determinants of IFN‐ γ levels and indeterminate results. Results: Significant quantitative differences in IFN‐ γ responses were observed across platforms ( p < 0.001). Active TB was the strongest predictor of IFN‐ γ release, with highest mean levels detected by TBF‐FIA (6.18 IU/mL), followed by TBF‐ELISA (3.11 IU/mL) and QFT‐Plus (2.80–2.96 IU/mL). TBF‐ELISA showed strong concordance with minimal bias versus QFT‐Plus (≤0.167 IU/mL), whereas TBF‐FIA demonstrated substantial proportional bias (>1.5 IU/mL). Indeterminate rates differed significantly (TBF‐FIA 13%, QFT‐Plus 8%, TBF‐ELISA 6%; Cochran’s Q test, p < 0.001). Demographic factors were not associated with assay failure; however, sample collection sites were significantly related. Notably, healthcare workers and TB contacts showed lower IFN‐ γ responses than expected. Conclusion: While all three IGRAs effectively differentiate TB infection status, the variability in IFN‐ γ responses and indeterminate rates is an indication that they may not be interchangeable. TBF‐FIA demonstrated the highest variability, requiring further investigation. The findings suggest that each test has its own strengths and limitations, thus, the need for selective use depending on the clinical setting and testing purpose.